Table 1

Impact outcomes (detection of new infections/uptake/turnaround time/linkage to care) associated with the use of rapid multiplexed STI diagnostic devices

Author, yearImpact outcomeMultiplex test typeResult
Pai et al, 201419New infectionIMT1/109 (0.9%) new infection of syphilis and 1/109 (0.9%) new infection of HIV detected with IMT
Pai et al, 2014*19New infectionIMT56/375 (14.9%) diagnosed with HIV, 75/375 (20.0%) with HBV, (37/375) 9.9% with syphilis, 2/375 (0.5%) with HCV
Pant Pai, et al 201921New infectionIMT30/510 (5.9%) new infections of HBV and 11/510 (2.2%) new infections of TV detected with IMT
Van Der Pol et al, 2017†29New infectionMolecular assay3.2% more infections of TV detected by molecular assay than culture and 71.4% more than wet mount
Pant Pai et al, 201921UptakeIMT99.4% increase for HCV IMT
79.0% increase for HBV IMT
42.0% increase for HIV IMT
99.6% increase for TV IMT
Le Roy et al, 201223TATMolecular assay4.5–5 hours for 50 samples (CT)
Longo et al, 201824TATIMT15 min (HIV, HBV and HCV)
Mboumba Bouassa et al, 201825TATIMT15 min (HIV, HBV, HCV)
Nuñez-Forero et al, 201626TATMolecular assay14 min (CT and NG)
Omoding et al, 201427TATIMT20 min (syphilis and HIV)
Causer et al, 201522TATMolecular assay91 min (CT and NG)
Pant Pai et al, 201921Retention in careIMT95.0% patients retained in care (HIV, HBV, HCV, TV)
Pant Pai et al, 201921Linkage to careIMT70.0% patients linked to care (HIV, HBV, HCV, TV)
Kalla et al, 201928Linkage to careIMT100.0% patients linked to care (HIV, HBV, HCV)
Menzato et al, 201818Linkage to careIMT100.0% patients linked to care (HIV)
  • *Study conducted in Canadian and Indian populations.

  • †Raw data were unavailable in the publication.

  • CT, Chlamydia trachomatis; HBV, hepatitis B virus; HCV, hepatitis C virus; IMT, immunochromatographic test; NG, Neisseria gonorrhoeae; STI, sexually transmitted infection; TAT, turnaround time; TV, Trichomonas vaginalis.